APGE Apogee Therapeutics, Inc. Common Stock

$65.50

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/17/2025

About Apogee Therapeutics, Inc. Common Stock

Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company is headquartered in Waltham, Massachusetts.

Website: https://www.apogeetherapeutics.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1974640
Address
221 CRESCENT ST., BUILDING 17, WALTHAM, MA, UNITED STATES
Valuation
Market Cap
$1.92B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
2.68
Performance
EPS
$-3.30
Dividend Yield
—
Profit Margin
0.00%
ROE
-33.20%
Technicals
50D MA
$35.67
200D MA
$45.19
52W High
$63.50
52W Low
$26.20
Fundamentals
Shares Outstanding
45M
Target Price
$93.88
Beta
nan

APGE EPS Estimates vs Actual

● Estimated
● Actual

APGE News & Sentiment

Nov 11, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Is Apogee Therapeutics Inc. ( APGE ) Outperforming Other Medical Stocks This Year?
Here is how Apogee Therapeutics Inc. (APGE) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Nov 10, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026. APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head ...
Nov 10, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing ...
Nov 03, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Apogee Therapeutics to Participate in Upcoming Conferences
SAN FRANCISCO and BOSTON, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , today announced that members of management will participate at the following investor conferences.
Nov 03, 2025 • Benzinga SOMEWHAT-BULLISH
Apogee Therapeutics to Participate in Upcoming Conferences - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and BOSTON, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( NASDAQ:APGE ) , today announced that members of management will participate at the following investor conferences.
Oct 30, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Wall Street Analysts Believe Apogee Therapeutics Inc. ( APGE ) Could Rally 69.3%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 69.3% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Sentiment Snapshot

Average Sentiment Score:

0.276
50 articles with scored sentiment

Overall Sentiment:

Bullish

APGE Reported Earnings

Aug 11, 2025
Jun 30, 2025 (Pre market)
-0.51 Surprise
  • Reported EPS: $-1.13
  • Estimate: $-0.62
  • Whisper: —
  • Surprise %: -82.3%
May 12, 2025
Mar 31, 2025 (Pre market)
-0.37 Surprise
  • Reported EPS: $-0.95
  • Estimate: $-0.58
  • Whisper: —
  • Surprise %: -63.8%
Mar 03, 2025
Dec 31, 2024 (Pre market)
-0.56 Surprise
  • Reported EPS: $-1.18
  • Estimate: $-0.62
  • Whisper: —
  • Surprise %: -90.3%
Nov 12, 2024
Sep 30, 2024 (Pre market)
-0.3 Surprise
  • Reported EPS: $-0.86
  • Estimate: $-0.56
  • Whisper: —
  • Surprise %: -54.1%
Aug 12, 2024
Jun 30, 2024 (Pre market)
-0.08 Surprise
  • Reported EPS: $-0.60
  • Estimate: $-0.52
  • Whisper: —
  • Surprise %: -15.4%
May 13, 2024
Mar 31, 2024 (Pre market)
-0.03 Surprise
  • Reported EPS: $-0.64
  • Estimate: $-0.61
  • Whisper: —
  • Surprise %: -4.9%
Mar 05, 2024
Dec 31, 2023 (Pre market)
0.17 Surprise
  • Reported EPS: $-0.32
  • Estimate: $-0.49
  • Whisper: —
  • Surprise %: 34.7%
Nov 13, 2023
Sep 30, 2023 (Pre market)
-0.1 Surprise
  • Reported EPS: $-0.51
  • Estimate: $-0.41
  • Whisper: —
  • Surprise %: -24.4%
Jul 17, 2023
Jun 30, 2023 (Pre market)
-2.08 Surprise
  • Reported EPS: $-3.78
  • Estimate: $-1.70
  • Whisper: —
  • Surprise %: -122.3%

Financials